News
-
-
-
PRESS RELEASE
Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
Vaderis Therapeutics closes $152 million Series B financing and starts global Phase 3 HEROIC study of engasertib for Hereditary Hemorrhagic Telangiectasia, marking a significant advancement in developing a therapy for the rare vascular disease -
-
-
PRESS RELEASE
Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy's Potential for Patients with Hereditary Hemorrhagic Telangiectasia
Vaderis Therapeutics announces publication of engasertib proof-of-concept study results in The New England Journal of Medicine, showing potential for Hereditary Hemorrhagic Telangiectasia patients
